Date Fruit Extract / MMP Cancer Research Results

DFE, Date Fruit Extract: Click to Expand ⟱
Features:
Dates (the fruit of Phoenix dactylifera) have been increasingly studied for their potential anticancer and cancer-preventive properties, mainly due to their rich phytochemical content and strong antioxidant activity.
Dates contain a broad spectrum of bioactive compounds linked to cancer prevention:
-Phenolic acids – e.g., ferulic acid, gallic acid, caffeic acid, and p-coumaric acid
-Flavonoids – e.g., quercetin, luteolin, apigenin
-Carotenoids – e.g., β-carotene, lutein
-Tannins, saponins, and sterols
-Dietary fiber and polysaccharides
These compounds have antioxidant, anti-inflammatory, and antiproliferative effects.

Date fiber and polyphenols foster beneficial gut bacteria (e.g., Bifidobacterium, Lactobacillus) that produce short-chain fatty acids (SCFAs), which protect the colon and may lower colon cancer risk.

Date Fruit Extract — a non-standardized botanical extract prepared from the edible fruit pulp of Phoenix dactylifera L., including cultivars such as Ajwa, Medjool, Hallawi, Sukkari, and others. It is classified as a complex food-derived phytochemical mixture rather than a single defined drug or active pharmaceutical ingredient. The standard abbreviation is DFE. Principal constituents vary substantially with cultivar, ripeness, processing, and extraction solvent, but commonly include phenolic acids such as gallic, ferulic, caffeic, protocatechuic, and p-coumaric acids; flavonoids such as quercetin, luteolin, apigenin, catechin, and epicatechin derivatives; carotenoids; condensed tannins; polysaccharides; and dietary fiber. Date fruit, date seed, leaf, pollen, and nanoparticle preparations are compositionally distinct and should not be treated as interchangeable with fruit-pulp extract.

Primary mechanisms (ranked):

  1. Induction of mitochondrial apoptosis in susceptible cancer cells, involving mitochondrial membrane depolarization, BAX/BCL-2 imbalance, caspase activation, and DNA fragmentation.
  2. Suppression of cancer-cell proliferation through cell-cycle arrest, with reported accumulation in G1 or G2/M phases depending on the extract, concentration, and tumor model.
  3. Redox modulation, including antioxidant protection in normal tissues but concentration-dependent ROS and mitochondrial ROS elevation in some cancer-cell models.
  4. Modulation of p53-associated stress and apoptotic signaling in responsive tumor cells.
  5. Anti-inflammatory activity through suppression of NF-κB-associated inflammatory signaling and inflammatory mediators, although direct tumor-specific evidence is limited.
  6. Secondary modulation of PI3K/AKT and related survival signaling, reported inconsistently and not established as a universal mechanism.
  7. Potential suppression of migration, clonogenic survival, angiogenic signaling, and tumor growth in selected preclinical models.
  8. Indirect colon-health effects through fermentable fiber and polyphenol interactions with the gut microbiota and production of short-chain fatty acids.

Bioavailability / PK relevance: No clinically validated pharmacokinetic profile exists for DFE as a standardized anticancer agent. Its polyphenols undergo incomplete intestinal absorption, extensive phase-II conjugation, microbial metabolism, and rapid systemic clearance. Consequently, circulating concentrations of individual parent compounds are generally much lower than concentrations used for direct cancer-cell cytotoxicity. Local gastrointestinal exposure and microbial metabolites may be more biologically relevant than systemic exposure after ordinary date consumption.

In-vitro vs systemic exposure relevance: Most antiproliferative studies use crude solvent fractions at tens to hundreds of micrograms per millilitre. These concentrations cannot be directly equated with plasma exposure after eating dates or taking an unstandardized extract. Extract-specific cytotoxic effects may reflect concentrated mixtures, solvent-selective enrichment, or interactions among multiple constituents. Common in-vitro exposures probably exceed achievable systemic concentrations from dietary intake.

Clinical evidence status: Preclinical. Evidence consists primarily of cell-culture studies, limited animal experiments, compositional studies, and small human dietary studies evaluating metabolic, inflammatory, or gastrointestinal outcomes. No randomized controlled oncology trial has established DFE as a cancer treatment, adjunctive anticancer therapy, radiosensitizer, or chemotherapy sensitizer. Date fruit and date-derived extracts are not approved by Health Canada, the FDA, or the EMA as anticancer drugs.

Safety and deployment: Whole dates are conventional foods and are generally well tolerated, but they contain substantial carbohydrate and sugar and may require portion control in people with impaired glycemic regulation. Extracts may differ markedly from the food in concentration, solvent residues, composition, and contaminant risk. Clinical interaction data with chemotherapy, anticoagulants, endocrine therapies, or targeted agents are inadequate. DFE should not be assumed to protect normal tissue selectively or improve anticancer treatment efficacy without direct combination studies.

Date Fruit Extract Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mitochondrial apoptosis MMP ↓; BAX ↑; BCL-2 ↓; caspase-3 ↑; apoptosis ↑ Apoptotic injury often ↓ in oxidative-damage models R, G Programmed cancer-cell death Best-supported direct anticancer mechanism, but demonstrated mainly with concentrated Ajwa or solvent-fraction extracts in vitro.
2 Cell-cycle control Proliferation ↓; G1 or G2/M arrest ↑ (model-dependent) ↔ G Cytostasis Cell-cycle phase varies by tumor line, cultivar, solvent fraction, concentration, and exposure duration.
3 ROS and mitochondrial oxidative stress ROS ↑; mitochondrial ROS ↑ (dose-dependent) ROS ↓; lipid peroxidation ↓; antioxidant capacity ↑ P, R Context-dependent redox modulation Cancer-cell pro-oxidant activity has been reported, while antioxidant protection predominates in normal-tissue injury models. Tumor selectivity is not clinically established.
4 p53 stress response p53 ↑; apoptotic signaling ↑ (model-dependent) ↔ R, G Stress-mediated growth suppression Reported in selected models and should not be generalized to p53-deficient or mutant-p53 tumors.
5 NF-κB inflammatory signaling NF-κB-associated survival and inflammation ↓ (limited evidence) Inflammatory signaling ↓ R, G Anti-inflammatory modulation More consistently supported in inflammatory or tissue-injury systems than in direct oncology experiments.
6 PI3K and AKT survival signaling PI3K/AKT ↓ (context-dependent) ↔ or AKT support ↑ in injury models R, G Survival-pathway suppression Not consistently measured across DFE studies and may partly reflect activities of individual phenolic constituents.
7 Clonogenic survival and tumor growth Colony formation ↓; tumor-cell burden ↓ in limited models ↔ G Long-term growth inhibition Evidence is substantially weaker than for established anticancer agents and remains extract-specific.
8 Migration and invasion Migration ↓; invasion-related signaling possibly ↓ ↔ G Potential antimetastatic activity Limited mechanistic data; MMP and epithelial-mesenchymal transition effects require further confirmation.
9 Angiogenic signaling VEGF-associated signaling possibly ↓ ↔ G Potential angiogenesis suppression Sparse evidence and not established as a primary effect of fruit-pulp extract.
10 NRF2 antioxidant response NRF2 modulation mixed (context-dependent) NRF2 and antioxidant enzymes ↑ R, G Secondary cytoprotective response NRF2 activation may protect normal tissues but could theoretically support antioxidant resistance in some cancers. Direct DFE tumor data are insufficient to define the net effect.
11 Gut microbiota and short-chain fatty acids Indirect colon-environment modulation Beneficial bacterial growth ↑; fermentation products ↑ G Local gastrointestinal and metabolic effect Human dietary evidence supports microbiota and bowel-environment effects more strongly than systemic anticancer activity.
12 Clinical Translation Constraint Effective exposure uncertain; extract composition heterogeneous Food-level tolerance generally favorable G Limits clinical interpretation Major constraints include cultivar and solvent variability, absent extract standardization, low systemic polyphenol exposure, high in-vitro concentrations, limited animal oncology evidence, and no controlled cancer trials.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
MMP, ΔΨm, mitochondrial membrane potential: Click to Expand ⟱
Source:
Type:
Destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Mitochondria are organelles within eukaryotic cells that produce adenosine triphosphate (ATP), the main energy molecule used by the cell. For this reason, the mitochondrion is sometimes referred to as “the powerhouse of the cell”.
Mitochondria produce ATP through process of cellular respiration—specifically, aerobic respiration, which requires oxygen. The citric acid cycle, or Krebs cycle, takes place in the mitochondria.
The mitochondrial membrane potential is widely used in assessing mitochondrial function as it relates to the mitochondrial capacity of ATP generation by oxidative phosphorylation. The mitochondrial membrane potential is a reliable indicator of mitochondrial health.
In cancer cells, ΔΨm is often decreased, which can lead to changes in cellular metabolism, increased glycolysis, increased reactive oxygen species (ROS) production, and altered cell death pathways.

The membrane of malignant mitochondria is hyperpolarized (−220 mV) in comparison to their healthy counterparts (−160 mV), which facilitates the penetration of positively charged molecules to the cancer cells mitochondria.
The MMP is a critical indicator of mitochondrial function, directly reflecting the organelle's capacity to generate ATP through oxidative phosphorylation.


Scientific Papers found: Click to Expand⟱
4454- DFE,    Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells
- in-vitro, Liver, HepG2
ROS↑, MMP↓, TumCCA↑, Apoptosis↑, selectivity↑, MMP↓, TumCCA↑,
4455- DFE,    Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest
- in-vitro, BC, MCF7 - in-vitro, Nor, 3T3
TumCCA↑, P53↑, BAX↑, Casp3↑, MMP↓, Fas↑, FasL↑, Bcl-2↓, Apoptosis↑, TumCP↓, TUNEL↑, eff↑, selectivity↑,
4456- DFE,    Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells
- in-vitro, Pca, PC3
TumCD↑, MMP↓, mt-ROS↑, Apoptosis↑, TumCCA↑,
6665- DFE,    Cytotoxic Effect of Phoenix dactylifera (Iraqi Date) Leaves and Fruits Extracts against Breast Cancers Cell Lines
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, CAL51 - in-vitro, BC, MCF7
TumCD↑, eff↓, selectivity↑, AntiCan↑, TumCP↓, MMP↓, cl‑Casp3↑, cl‑PARP↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,   mt-ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 5,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 3,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Fas↑, 1,   FasL↑, 1,   TumCD↑, 2,   TUNEL↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 4,  

Migration(tgid=13) ⓘ

TumCP↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↓, 1,   eff↑, 1,   selectivity↑, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,  
Total Targets: 20

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: MMP, ΔΨm, mitochondrial membrane potential
4 Date Fruit Extract
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:371  Target#:197  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page